BeOne Medicines (BEIGF) Total Debt (2015 - 2026)

BeOne Medicines (BEIGF) has reported Total Debt for 12 consecutive years, with $1.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt rose 12.42% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 12.42% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 45.48% from the prior year.
• Total Debt was $1.1 billion for Q2 2026 at BeOne Medicines, down from $1.1 billion in the prior quarter.
• Over five years, Total Debt peaked at $2.5 billion in Q3 2025 and troughed at $488.1 million in Q1 2023.
• A 5-year average of $966.0 million and a median of $939.1 million in 2025 frame the typical range for Total Debt.
• The widest YoY moves for Total Debt: up 133.93% in 2025, down 45.48% in 2025.
• Over 5 years, Total Debt stood at $538.1 million in 2022, then surged by 64.65% to $886.0 million in 2023, then soared by 111.01% to $1.9 billion in 2024, then plunged by 45.48% to $1.0 billion in 2025, then grew by 5.28% to $1.1 billion in 2026.
• The last three Total Debt figures came in at $1.1 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.